Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, China.
North Sichuan Medical College, Nanchong, 637000, China.
Eur Arch Otorhinolaryngol. 2023 Dec;280(12):5409-5416. doi: 10.1007/s00405-023-08157-9. Epub 2023 Aug 2.
To establish a nomogram for prediction of prognosis in EGFR-positive advanced nasopharyngeal carcinoma (NPC) patients who were treated with induction chemotherapy (IC) and concurrent chemoradiotherapy (CCRT). The clinical data of 124 NPC patients who received IC sequential CCRT combined with targeted therapy at the Department of Oncology of the Affiliated Hospital of North Sichuan Medical College between June 2017 and September 2022 were retrospectively reviewed. Logistic regression analysis was used to identify the prognostic factors for building the nomogram.
Multifactorial regression analysis showed that the use of targeted drugs and T stage were independent factors of prognosis (p < 0.05) and the equation Y = 0.476 + 2.733X1 + - 0.758 × 2 (Y = efficacy, X1 = targeted drug therapy, X2 = T stage) was obtained. Then, a prognostic nomogram prediction model was constructed. The prediction model was validated internally for 1000 times using the Bootstrap resampling method with an accuracy of 79.29%. The calibration curve suggests that the predicted values fit well with the true values. The clinical decision curve (DCA) shows that the model has good clinical predictive value.
The use of targeted therapy significantly improved the prognosis of patients with EGFR-positive advanced NPC. For advanced NPC patients with T1 and T2 stages, IC sequenced with CCRT is more effective, and the addition of targeted therapy can further improve patients' prognosis. For advanced NPC patients with T3 and T4 stages, IC sequenced with CCRT is ineffective, and the addition of targeted therapy can significantly improve patient prognosis.
建立一个列线图,用于预测接受诱导化疗(IC)和同期放化疗(CCRT)的表皮生长因子受体(EGFR)阳性晚期鼻咽癌(NPC)患者的预后。回顾性分析 2017 年 6 月至 2022 年 9 月在川北医学院附属医院肿瘤科接受 IC 序贯 CCRT 联合靶向治疗的 124 例 NPC 患者的临床资料。采用 logistic 回归分析确定建立列线图的预后因素。
多因素回归分析显示,靶向药物的使用和 T 分期是独立的预后因素(p<0.05),并得出方程 Y=0.476+2.733X1-0.758×2(Y=疗效,X1=靶向药物治疗,X2=T 分期)。然后,构建了一个预后列线图预测模型。使用 Bootstrap 重采样方法对该预测模型进行了 1000 次内部验证,准确率为 79.29%。校准曲线表明预测值与真实值拟合良好。临床决策曲线(DCA)表明该模型具有良好的临床预测价值。
靶向治疗显著改善了 EGFR 阳性晚期 NPC 患者的预后。对于 T1 和 T2 期的晚期 NPC 患者,IC 序贯 CCRT 更有效,联合靶向治疗可进一步提高患者的预后。对于 T3 和 T4 期的晚期 NPC 患者,IC 序贯 CCRT 无效,联合靶向治疗可显著改善患者的预后。